glp 1 and liver enzymes GLP-1 Receptor Agonists in Non-Alcoholic Fatty Disease: Current Evidence Future Perspectives GLP-1 medicine improves liver health

in Spain, its current prevalence ranges between 2833%11,12 and it is a recognized as a cardiovascular risk factor and increases the mortality in this population.1315 Furthermore, in patients with DM2 and advanced CKD there are limitations in the prescription of certain antihyperglycemic drugs (e.g., metformin or sulfonylureas) and there is an increased risk of hypoglycemia with antihyperglycemic treatment,16 a complication that is associated with increased cardiovascular risk17 and hinders the achievement of glycemic control targets

Additionally, while high-fat fed mice with leptin resistance display increased GLP-1 content in the ileum and the colon, both fasting and glucose-stimulated GLP-1 secretion are significantly reduced in these mice (Anini and Brubaker, 2003), which may provide a link between leptin resistance in L cells and the reduced late phase (60160 min) total and active GLP-1 secretion in patients with diabetes compared to healthy individuals (Vilsboll et al., 2001)

If the results are neutral or negative, the heart rate and arrhythmia signals from phase 2 will receive much more scrutiny

Nail-patella-elbow syndrome

However, its mechanism of action needs to be further studied (Zhao et al., 2011)

The Wegovy pill in the UK The MHRA approved the Wegovy pill on 11 June 2026, the first GLP-1 weight-loss tablet licensed in the UK